Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meenu Kesarwani

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
A novel hyperactive <i>BCR::ABL1</i> <sup><i>e6a3</i></sup> variant confers resistance to combined asciminib plus ponatinib therapyValentina Nardi, Joshua Schwieterman, Sekhu Ansari, et al.
Haematologica|September 29, 2018
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromesPeipei Lin, Yanling Ren, Xiaomei Yan, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
A novel hyperactive <i>BCR::ABL1</i> <sup><i>e6a3</i></sup> variant confers resistance to combined asciminib plus ponatinib therapyValentina Nardi, Joshua Schwieterman, Sekhu Ansari, et al.
Haematologica|September 29, 2018
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromesPeipei Lin, Yanling Ren, Xiaomei Yan, et al.
Pageof 3